<![CDATA[COPERNICUS Safety Data and Pragmatic Trial Design]]>

Trial StartamivantamablazertinibNeutral

AI Analysis

Summary

Dr. Estelamari Rodriguez describes the COPERNICUS trial, a pragmatic study evaluating first-line subcutaneous amivantamab plus lazertinib with supportive care in EGFR-mutated advanced NSCLC. The study is open at Sylvester Comprehensive Cancer Center.

Clinical Trial Data

Importance:3/10

Sentiment:

0.00

COPERNICUS trialpragmatic trial designsafety datafirst-line treatmentEGFR-mutated NSCLCsubcutaneous amivantamablazertinibsupportive care

Related Companies

$CMHSF $TRAX

Read the original article

Published by Cancer Network on October 12, 2026 12:05 PM

Read Original